Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep 12;24(18):3316.
doi: 10.3390/molecules24183316.

Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis

Marcin Feldo  1 , Magdalena Wójciak-Kosior  2 , Ireneusz Sowa  3 , Janusz Kocki  4 , Jacek Bogucki  5 , Tomasz Zubilewicz  6 , Jan Kęsik  7 , Anna Bogucka-Kocka  8
Affiliations
Clinical Trial

Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis

Marcin Feldo et al. Molecules. .

Abstract

Diosmin is a natural compound with a wide range of biological activity, e.g., it improves lymphatic drainage, supports microcirculation, and increases venous tone, and venous elasticity, hence, it is applied in the pharmacotherapy of chronic venous disorders (CVD). The aim of this study was to assess the correlation between diosmin administration (2 × 600 mg daily) in patients suffering from CVD and the levels of selected factors influencing angiogenesis, which are involved in CVD pathophysiology. Thirty-five CVD patients were examined. Levels of plasma tumor necrosis factor alpha (TNF alpha), vascular endothelial growth factor (VEGF-A and VEGF-C); angiostatin, interleukin 6 (IL-6), fibroblast growth factor 2 (FGF2); and plasminogen (PLG) were measured with an Elisa assay before and after three months of diosmin administration. The clinical symptoms of CVD were monitored using ultrasound images, echo Doppler assay, visual analogue scale (VAS), and measurement of the leg circumference. The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. A significant (p < 0.05) decrease in edema and the average leg circumference of the patients was observed after the therapy. Diosmin influences the angiogenic and inflammatory mechanisms involved in the pathophysiology of edema presented in patients with a different class of CVD.

Keywords: angiostatin; chronic venous disorders; diosmin; fibroblast growth factor 2; interleukin 6; plasminogen; tumor necrosis factor alpha; vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Ultrasound images of the perivascular space in a patient before (a) and after (b) 3 months of diosmin treatment.
Figure 2
Figure 2
Plasma level of VEGF-A (a), VEGF-C (b), TNF alpha (c), angiostatin (d), IL6 (e), FGF2 (f) and plasminogen (g) before (T0) and after three months (T3m) of diosmin treatment. * p < 0.05, ** p < 0.001, *** p < 0.01.
Figure 2
Figure 2
Plasma level of VEGF-A (a), VEGF-C (b), TNF alpha (c), angiostatin (d), IL6 (e), FGF2 (f) and plasminogen (g) before (T0) and after three months (T3m) of diosmin treatment. * p < 0.05, ** p < 0.001, *** p < 0.01.
Figure 3
Figure 3
Comparison of the levels of the investigated factors in the C2, C3, and C4 groups before (T0) and after three months of diosmin treatment (T3m). The data followed by the different letters are statistically significant: (a) and (b) lack of statistically significant differences (p > 0.05), (c) p = 0.005 for C2 and C3; p = 0.0001 for C2 and C4; (d) p = 0.05; (e) p = 0.01 for C2 and C3; p = 0.001 for C2 and C4; (f) p = 0.01 for C2 and C3; p = 0.001 for C2 and C4.
See this image and copyright information in PMC

References

    1. Bogucka-Kocka A., Woźniak M., Feldo M., Kocki J., Szewczyk K. Diosmin—Isolation techniques, determination in plant material and pharmaceutical formulations and clinical use. Nat. Prod. Commun. 2013;8:545–550. doi: 10.1177/1934578X1300800435. - DOI - PubMed
    1. Liu W.Y., Liou S.S., Hong T.Y., Liu I.M. The benefits of the citrus flavonoid diosmin on human retinal pigment epithelial cells under high-glucose conditions. Molecules. 2017;22:2251. doi: 10.3390/molecules22122251. - DOI - PMC - PubMed
    1. Batchvarov I.V., Batselova M.G., Damyanov I.I. One-year diosmin therapy (600 mg) in patients with chronic venous insufficiency—Results and analysis. J. Biomed. Clin. Res. 2010;3:51–54.
    1. Lyseng-Williamson K.A., Perry C.M. Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency. Venous ulcers and haemorrhoids. Drugs. 2003;63:71–100. doi: 10.2165/00003495-200363010-00005. - DOI - PubMed
    1. Tong N., Zhang Z., Zhang W., Qiu Y., Gong Y., Yin L., Qiu Q., Wu X. Diosmin Alleviates Retinal Edema by Protecting the Blood-Retinal Barrier and Reducing Retinal Vascular Permeability during Ischemia/Reperfusion Injury. PLoS ONE. 2013;8:e61794. doi: 10.1371/journal.pone.0061794. - DOI - PMC - PubMed

Publication types

MeSH terms